Results 91 to 100 of about 4,565 (192)
Potential Drug-Drug Interactions With Tyrosine Kinase Inhibitors [PDF]
, 2019 През последните години се наблюдава голям напредък при лечението на туморните заболявания поради въвеждането на нови фармакологични подходи като таргетната терапия и имунотерапията.
Georgiev, Kaloyan +2 more
core +2 more sources
Lung Cancer: Targets and Therapy, 2018 Lei Deng,1 Janaki Sharma,2 Elizabeth Ravera,2 Balazs Halmos,2 Haiying Cheng2 1Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Oncology, Montefiore Medical Center/Albert Einstein College of
Deng L +4 more
doaj
Brigatinib Approved, but Treatment Role Uncertain [PDF]
Cancer Discovery, 2017 Abstract The FDA has approved the ALK inhibitor brigatinib for patients with metastatic non-small cell lung cancer who cannot take crizotinib or whose disease worsened despite its use. The decision was based upon results of a phase II study that assessed two drug doses, with overall response rates of 45% and 56% respectively.
openaire +2 more sources
Expression and amplification of HER2 and molecular markers of signal activation in the advanced or metastatic lung carcinoma [PDF]
, 2018 Die Arbeit beleuchtet die Bedeutung des Signalmoleküls HER2 im Rahmen der intrazellulären Signalweiterleitung sowie seine Bedeutung als prognostischer bzw. prädiktiver Marker im fortgeschrittenen bzw.
Huber, Ulrich Cyril
core
A comparative evaluation of alectinib for ALK-positive non-small-cell lung cancer: A systematic review [PDF]
Background: Lung cancer, a significant global health challenge, notably the non-small-cell lung cancer (NSCLC) subtype, is a topic of utmost importance.
Emmanuel, Sonya +9 more
core +2 more sources
Personalised treatment of non-small-cell lung cancer patients — review of current evidence [PDF]
, 2018 The increasing number of scientific reports on the new-generation tyrosine kinase inhibitors and immunological checkpoint inhibitors in the management of patients with non-small-cell lung cancer (NSCLC) results in the necessity of frequent guidelines ...
Krzakowski, Maciej, Zysk, Rafal
core +2 more sources
Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib
Chinese Journal of Lung CancerThe discovery of anaplastic lymphoma kinase (ALK) tyrosine kinase gene rearrangement mutations in non-small cell lung cancer (NSCLC) has driven continuous advancements in ALK-targeted therapies.
Jia YU, Shengxiang REN
doaj +1 more source
Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma [PDF]
, 2022 Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and a leading cause of death worldwide. The hyperactivated cell survival signaling pathways cause resistance to conventional chemotherapeutics so that targeted therapies could ...
Cetin-Atalay, Rengul +2 more
core
Brigatinib bei ALK-positivem NSCLC [PDF]
Im Focus Onkologie, 2017 Die meisten mit Crizotinib behandelten Patienten mit ALK-positivem NSCLC erleiden in absehbarer Zeit ein Rezidiv. In dieser Studie wurden zwei Dosen des Zweitgenerations-ALK-Inhibitors Brigatinib bei solchen Patienten gepruft.
openaire +1 more source